Using markers to improve pancreatic cancer screening and surveillance: a multi-center study

使用标志物改善胰腺癌筛查和监测：一项多中心研究

基本信息

批准号：
10526649
负责人：
Michael G. Goggins
金额：
$ 78.66万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-18 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10526649
关键词：
Accounting Affect Age Aneuploidy Artificial Intelligence Biological Markers Biological Specimen Banks Blinded Blood Blood Tests Blood specimen CA-125 Antigen CA-19-9 Antigen Cancer Etiology Case-Control Studies Cessation of life Characteristics Clinical Trials Cyst Fluid Data Databases Detection Development Diabetes Mellitus Diagnosis Diagnostic Diagnostic Sensitivity Diagnostic Specificity Diagnostic tests Drops Early Diagnosis Evaluation Studies Family Future Genes Genetic Genotype Guidelines High grade dysplasia Icterus Image Incidence Individual Juice Lead Magnetic Resonance Magnetic Resonance Spectroscopy Malignant Neoplasms Malignant neoplasm of pancreas Metabolic Metabolic syndrome Methods Multicenter Studies Outcome Pancreas Pancreatic Cyst Pancreatic Ductal Adenocarcinoma Patient-Focused Outcomes Patients Performance Plasma Predisposition Prevalence Recording of previous events Reference Values Research Personnel Resectable Resolution Resources SEER Program Sampling Screening for cancer Serum Specificity Specimen Subgroup Testing Time Tissue Banks Tissue imaging Tissues Training Tumor Markers Variant X-Ray Computed Tomography advanced disease base cancer diagnosis cancer imaging case control clinical diagnosis cohort deep learning design verification diagnostic panel disorder control early detection biomarkers genetic testing genetic variant glycosylation high risk improved improved outcome microbiome novel marker pancreas imaging pancreatic cancer patients pancreatic juice pancreatic neoplasm patient subsets pre-clinical programs prospective sample collection screening surveillance imaging

项目摘要

Abstract Patients diagnosed with Stage I pancreatic cancer have a much better outcome than most patients who present with advanced disease. The Cancer of the Pancreas Screening (CAPS) study currently follows a familial/genetic “high-risk” cohort of ~1500 patients undergo regular pancreatic surveillance. Recent results from the CAPS program indicate that most patients who maintain regular surveillance are down-staged, many are diagnosed with Stage I pancreatic cancer and achieve long-term survival. Circulating tumor marker tests are not currently used for pancreas surveillance, but we propose to evaluate blood tests for patients undergoing pancreatic surveillance. We will evaluate the use of tumor marker gene tests to better define an individual’s tumor marker normal reference range. We will evaluate the use of plasma MR spectroscopy as a diagnostic test that utilizes artificial-intelligence methods to detect subtle circulating metabolic changes associated with having pancreatic cancer. We will also determine if blood biomarker changes occur before the diagnosis of pancreatic cancer in our cohort. The addition of annual blood tests to pancreatic surveillance is expected to improve the detection of early-stage pancreatic cancer. We will continue to evaluate the long-term outcomes of patients in our cohort and bank biospecimens for future biomarker studies.

抽象的诊断为 I 期胰腺癌的患者比大多数患者有更好的结果患有晚期疾病的患者进行胰腺癌筛查 (CAPS) 研究。目前跟踪一个由约 1500 名患者组成的家族/遗传“高风险”队列，接受定期胰腺检查 CAPS 计划的最新结果表明，大多数患者保持定期监测。监测被降低阶段，许多人被诊断出患有 I 期胰腺癌并达到循环肿瘤标志物检测目前不用于胰腺监测，但我们建议对接受胰腺监测的患者进行血液检查评估。将评估肿瘤标志物基因测试的使用，以更好地确定个体肿瘤标志物的正常情况我们将评估等离子体 MR 光谱作为诊断测试的用途。利用人工智能方法来检测与相关的微妙循环代谢变化我们还将确定在患有胰腺癌之前是否发生血液生物标志物变化。在我们的队列中诊断出胰腺癌每年对胰腺进行血液检查。预计监测将改善早期胰腺癌的检测。评估我们队列中患者的长期结果并为未来存储生物样本生物标志物研究。